DOI: 10.48309/JMPCR.2024.424911.1034

and Pharmaceutical Chemistry Research (D) SAMI

# FULL PAPER

# Systematic review and meta-analysis of narcolepsy management during the covid-19 pandemic

Mansour Deylami<sup>a,</sup> \*<sup>(D)</sup> | Majid Vatankhah<sup>b</sup><sup>(D)</sup> | Tayyebeh Zarei<sup>b</sup><sup>(D)</sup> | Ehsan Rahmanian<sup>c</sup><sup>(D)</sup> | Farshid Javdani<sup>c</sup><sup>(D)</sup> | Shahram Shafa<sup>c</sup><sup>(D)</sup> | Hasan Zabetian<sup>c</sup><sup>(D)</sup> | Minou Najar Nobari<sup>d</sup><sup>(D)</sup> | Kaveh Hedayati Emami<sup>e</sup><sup>(D)</sup> | Fateme Maleki<sup>(D)</sup> | Amin Shafiei<sup>c</sup><sup>(D)</sup> | Vida Hafezi<sup>g</sup><sup>(D)</sup> | Roohie Farzaneh <sup>h</sup><sup>(D)</sup> | Mohammad Sadegh Sanie Jahromi<sup>c</sup><sup>(D)</sup>

<sup>a</sup>Assistant Professor of Anesthesiology, Department of Anesthesiology and Critical Care, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

<sup>b</sup>Anesthesiology, Critical Care and Management Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Pain

<sup>c</sup>Research Center for Social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran.

<sup>d</sup>Orofacial Pain and Dysfunction and Sleep Disorders Department, School of Dentistry, UCLA, Los Angeles, California, US.

<sup>e</sup>Department of Anesthesiology and Critical Care, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Department of Emergency Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran

<sup>g</sup>Student Research Committee, Alborz University of Medical Sciences, Alborz, Iran.

<sup>h</sup>Department of Emergency Medicine, Faculty of Medicine, Mashhad University of Medical sciences, Mashhad, Iran.

*Corresponding Author:									
Mansour Deylami									
Email: mansour.deylami@gmail.com									
Tel: +989111713017									

The concern has recently been raised for disease status and management of people with narcolepsy after initiation of COVID-19 pandemic. Here, we evaluated the literature to determine how the COVID-19 pandemic has impacted the lives of narcolepsy patients. This was a systematic review and meta-analysis study on online databases of Web of Science, PubMed, Scopus, and ScienceDirect using keywords of "Narcolepsy", "Sleepiness " "cataplexy", "nightmare", "nocturnal sleep", "COVID-19" "COVID-19" "Pandemic", "SARS-COV2", and "Coronavirus", looking for observational studies. Statistical analyses were performed by CAM software with significance level being considered at under 0.05 as statistically significant. Total number of 9 studies were included with 607 patients with narcolepsy. With a heterogeneity of 99.94%, pooled mean differences (MD) of Epworth Sleepiness Scale (ESS) scores before and after the pandemic/lockdowns was -1.54 (95%CI: -1.55 to -1.53, P<0.01). The most prevalently increased symptom among the narcolepsy patients was naps taken during the day (58.81%, 95%CI of 50.85 to 66.34) followed by the increased appetite (45.15%, 95%CI of 28.91 to 62.49). Our study shows that disease status of narcolepsy patients is affected by COVID-19 pandemic. We can assist narcolepsy patients in this challenging position by being aware of their unique demands during the COVID-19 illness and sympathetic to their sensitivity.

#### **KEYWORDS**

COVID-19; narcolepsy; meta-analysis; sleep; pandemic.

#### Introduction

Narcolepsy is a neurological disorder that affects the control of sleep and wakefulness [1]. Individuals affected by narcolepsy experience daytime sleepiness and intermittent, uncontrollable periods of sleeping during the day. These sudden attacks of sleep may occur during any type of activity and at any time of the day [2]. Drowsiness during the day has led to mistakes and sometimes human accidents and tragedies in industrial societies, and variable statistics have been reported in terms of accidents and deaths caused by narcolepsy [3]. Narcolepsy management by medications is also one of the other ways to treat sleep

Journal of Medicinal and Pharmaceutical Chemistry Research Page | 293

attacks, which is used in some people with severe and damaging symptoms of this disorder [4]. Some drugs, such as those in the stimulant group as well as the Modafinil, Methylphenidate, and amphetamines are mainly used to treat this sleep disorder [4]. Human life has faced serious challenges with spread of the COVID-19 pandemic [5]. People were advised to stay at home, required to use personal protective equipment, and many countries' economies suffered a recession [6]. Most medical emergencies have experienced interruptions in standard care; this affected the regularity of providing care for other diseases than COVID-19 [7]. Quarantine measures led to changes in bedtime and waking-up schedules, contributing to circadian misalignment for narcolepsy patients [8]. COVID-19 lockdowns affected the sleep quality and daytime condition of narcolepsy patients, emphasizing the broader impact on well-being [9]. Some narcolepsy patients faced job loss, leading to altered working/studying conditions and potential lifestyle shifts [10]. Effects of the COVID-19 pandemic's quarantines and restrictive roles has been well studied on both acute [7,11]. and chronic diseases [12].Recently, some studies have focused on the same issue for the narcolepsy patients. Here, we conducted a systematic review of the literature to determine how the COVID-19 pandemic affected narcoleptic patients' lives. By knowing about the special needs of narcolepsy patients during the COVID-19 disease and being sensitive to their vulnerability, we can help them in this difficult situation. The objective of this study was to compare clinical status of narcoleptic patients, before and after COVID-19.

# Methods

We conducted a systematic review and metaanalysis from July to November, 2022 based on the PRISMA statement. The objective of this study was to examine the effect of COVID-19 pandemic on narcolepsy patients.

# Search strategy

The required information has been collected in online databases of Web of Science, PubMed, Scopus, and ScienceDirect using keywords of "Narcolepsy", "Sleepiness ", "cataplexy", "nightmare", "nocturnal sleep", "COVID-19", "Pandemic", "SARS-COV2", and "Coronavirus". The period selected for searching articles was from 2019 to 2022. To identify and cover more published articles, after searching the databases, several authoritative journals in this field were also searched manually. Reference lists of full text eligible papers were also manually searched for potentially relevant papers. All search steps were performed independently by two authors.

D) SAMI

# Eligibility

The inclusion criteria included studies reporting indices of hypersomnia before pandemic compared with during the pandemic in patients with narcolepsy of any type. Likewise, studies reporting these indices before and during a lockdown and quarantine were included. We did not impose any limitations on age or study area and only included English language papers. The exclusion criteria comprised of interventional studies, articles presented in conferences, case reports, letters to the editor, and non-peer reviewed sources. Two independent evaluators performed eligibility assessments third researcher and а judged anv disagreement in selection of studies.

# Data extraction

All articles were evaluated by two evaluators using a checklist after extracting them from the desired reports. To extract data, a data extraction form was designed manually in the Excel software environment, and the extracted information in this form included: author's name, year of publication of the article, name of the country, characteristics and number of participants, the methods of assessment of



narcolepsy, reported changes in symptoms, and numerical objective assessments of the narcolepsy before and after lockdowns. Variables of Epworth Sleepiness Scale (ESS), frequency of cataplexy, appetite changes, disturbed nocturnal sleep, naps taken per day, nightmares, and sleep attacks were extracted for meta-analyses.

#### Quality assessment

Joanna Briggs Institute (JBI) tool was used for critical appraisal of the papers with retrospective study design. This included 8 questions about the different methodological aspects of the study. Studies with less than 5 forgathered criteria were considered as low quality. Based on the mentioned criteria, there should be clear and well-defined inclusion criteria outlining participant characteristics, study design, and relevant interventions. In addition, the subjects and settings should be clearly described. Valid and reliable exposure and outcome measures as well as employing standard methodologies are essential to ensure the accuracy of collected data. The identification of potential confounding factors and the implementation of strategies to address them, such as matching or statistical adjustments, demonstrate a robust study design. Ultimately, the use of appropriate statistical methods and transparent reporting contributes to the overall appraisal of study quality, ensuring the validity and reliability of the findings in the context of the research synthesis.

#### Statistical analysis

The effect size was flexibly selected based on the reported outcomes in included studies. Qualitative measures were pooled in form of event rates in one group. Event rates of subjective changes in symptoms of narcolepsy before and after lockdowns were used in calculations. In case of quantitative data, where data of before and after lockdown were provided, differences in means were pooled by random model effect size. P-value of under 0.05 was considered as statistically significant. То perform meta-analysis, CMA 3 (Comprehensive Meta-Analysis) software was used. I2 above 50% was considered as heterogeneous in study based on the Q statistic.

#### Results

After removing the articles that were weakly related to the objectives of the study and selecting the original articles, the list of sources of the selected articles was also searched to increase the certainty of identifying and reviewing the existing articles.

Total number of 9 studies was included in our review as listed in Table 1. Total number of 607 patients with narcolepsy was evaluated. ESS changes were compared before and after pandemic/lockdown in 4 studies. Other studies had only reported ESS measures to address the severity of disease.

Pooling the mean differences (MD) of Epworth Sleepiness Scale (ESS) scores before and after the pandemic, 4 studies were included in which Postiglione et al. study had expressed their results based on the 3 different groups of patients, that we defined each of them as an independent sample for pooling. Finally, with a heterogeneity of 99.94%, pooled MD was -1.54 (95%CI: -1.55 to -1.53, P<0.01), as displayed in Figure 1. Funnel plot in Figure 1 (right side), does not show evidence of asymmetry. Egger's test revealed no publication bias (P=0.472).

SAMI

Author	Country	Study design	Period	Time	Narcolepsy type	Z	COVID-19 infection	Measuring tool	Age	Male
Pech de Laclause	France	retrospectiv e analytical	April-2020	during lockdown	NT1	77	NR	multiple- choice questions	15.16 ±3.52	NR
Filardi	Italy	retrospective analytical	November 2019 and January 2020	during lockdown	NT1	30	NR	actigraphy; ESS	13.27±3.47	11
Postiglione	Italy	retrospective analytical	16 April to 12 May 2020	during lockdown	NT1	50	NR	telephone neurologic consultation	35.0 ± 19.4	20
Rodrigues Aguilar	Brazil	retrospective analytical	Jun-20	during pandemic compared with before pandemic	52 NT1; 24 NT2	76	NR	multiple-choice questions, Epworth Sleepiness Scale (ESS	36.9 ± 11.7	24
Scarpelli S	Italy	case-control	March 10, 2020, to May 4, 2020	during lockdown	34 NT1; 12 NT2	43	NR	multiple-choice questions	NR	18
Barateau	France	retrospective analytical	March and May 2020	during lockdown	NT1/2	102	NR	ESS; NSS	40.11 ± 19.54	NA
Nigam	France	retrospective analytical	May 2020	during lockdown	73 NT1; 58 NT2	131	6	ESS	37.5 ± 14.1NT1; 40.2 ±14.6NT2	48
D'Anselmo	Italy	case-control	June to November 2019	during lockdown	NT1	52	NR	ESS; NSS	33.56 ±11.59	14
Zhao	China	case- control	Jan 1, 2017 to Jan 1, 2021	during lockdown	34 NT1; 12 NT2	46	NR	ESS	20.76 ± 8.99	57

### **TABLE 1** Characteristics of included studies



FIGURE 1 Forest plot pooled mean differences of ESS before and after pandemic and its funnel plot

In forest plot (left), the size of each circle represents the sample size and the lines drawn on each side of the square represent the 95% confidence interval for each study; Funnel plot (right side) shows the symmetric distribution of log differences in mean based on the standard errors. We pooled event rate of selfreported increase in symptoms of narcolepsy under random effect size for the studies with high heterogenicity (>75%) and fixed effect size for the rest. The most prevalently increased symptom among the narcolepsy patients was naps taken during the day (58.81%, 95%CI of 50.85 to 66.34) followed by the increased appetite (45.15%, 95%CI of 28.91 to 62.49). Other symptoms were less frequently increased, as well as the disturbed nocturnal sleep, nightmares, frequency of cataplexy, as presented in Table 2. No publication bias assessment was performed as epidemiologic proportional data does not require.

<b>TABLE 2</b> Meta-analysis summary of the event rate of self-reported increase in symptoms of
narcolepsy

	Event	total	event	95% CI	<b>I</b> <sup>2</sup>	
	count		rate	Lower limit	Upper limit	
Increased frequency of cataplexy						
Laclaus <i>et al</i> .	22	47	46.81	33.16	60.95	91.52
Aguilar <i>et al</i> .	13	76	17.11	10.2	27.27	
Total	35	123	29.93	9.35	63.9	
Increased appetite						82.79
Laclaus <i>et al.</i>	31	77	40.26	29.94	51.52	
Zhao <i>et al.</i>	15	46	32.61	20.71	47.27	
Aguilar <i>et al</i> .	47	76	61.84	50.5	72.02	
Total	93	199	45.15	28.91	62.49	
Increased disturbed nocturnal slee	p					52.62
Aguilar <i>et al</i> .	33	76	43.42	32.78	54.71	
Postiglione <i>et al.,</i> Unchanged schedule	24	77	30	14.14	52.72	
Postiglione <i>et al.</i> , Working/studying at home	6	20	13.64	4.46	34.79	
Postiglione et al., Lost occupation	3	22	12.5	1.73	53.73	
Laclaus <i>et al.</i>	1	8	31.17	21.85	42.31	

Systematic review and meta-analysis of	Journal of Medicinal and Pharmaceutical	- 🛞 SAMI	Page	297		
			Chemistry Research			
Total	67	203	26.83	18.67	36.94	
Increased naps taken						0
Laclaus <i>et al.</i>	44	77	57.14	45.92	67.68	
Aguilar <i>et al.</i>	46	76	60.53	49.19	70.84	
Total	90	153	58.81	50.85	66.34	
Increased nightmares						
Laclaus <i>et al.</i>	23	77	29.87	20.73	40.96	63.19
Postiglione <i>et al.,</i> Unchanged schedule	2	20	1.00	2.51	32.38	
Postiglione <i>et al.</i> , Working/studying at home	1	22	4.55	6.40	26.15	
Postiglione et al., Lost occupation	0	8	5.56	3.4	50.47	
Total	26	127	12.94	4.18	33.59	
Increased sleep attacks						84.89
Laclaus <i>et al.</i>	22	77	28.57	19.61	39.61	
Nigam <i>et al.</i>	18	131	13.74	8.83	20.76	
Total	40	208	20.16	9.29	38.37	

### Quality assessment

As indicated in Table 3, inclusion criteria were clear in all studies and patients with narcolepsy based on the ICSD-3; International classification of sleep disorders-third edition had been selected. Except for the Zhao study, all studies had clear settings, periods of study, and subjects. Exposure that was lockdown or pandemic effects were not well demonstrated in most studies and only Aguilar et al., Postiglione et al., and Zhao et al. studies evaluated effects of lockdowns on working/studying schedules. Confounding factors were identified in most circumstances but adjustments for decreasing their negative consequences were not performed in studies.

	Pech de Laclause	Filardi	Postiglione	Rodrigues Aguilar	Scarpelli S	Barateau	Nigam	D'Anselmo	Zhao
Clear inclusion criteria	Υ	Υ	Υ	Ŷ	Υ	Υ	Υ	Υ	Υ
Clear subjects and settings	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Ν
Valid and reliable exposure measure	Ν	Ν	Υ	Υ	Ν	Ν	Ν	Ν	Υ
Standard measures	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ
Identified confounding factor	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ
Strategies dealing confounding factor	Ν	Ν	Υ	Ν	Ν	Ν	Υ	Ν	Ν
Valid and reliable outcome measure	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ
Appropriate statistics	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ
Overall appraisal									
	included	included	Included	included	included	included	included	included	included

TABLE 3 Critical appraisal of included studies

Y: Yes; and N: No.



Journal of Medicinal and Pharmaceutical Chemistry Research

#### Discussion

We conducted a systematic review and metaanalysis of effects of COVID-19 pandemic on clinical conditions of narcoleptic patients. Our study showed that Epworth Sleepiness Scale (ESS) scores in narcolepsy patients has significantly decreased after the initiation of pandemic or lockdowns (-1.54, 95%CI: -1.55 to -1.53; P<0.01). In addition, the data showed that number of naps taken during the day increased significantly. These two findings are consistent with the known effects of daytime naps on reducing sleepiness in narcoleptic patients. Furthermore, the nighttime symptoms of narcolepsy did not differ with the pandemic. As we know that when subjective sleepiness, assessed by ESS, is higher than 10, daytime sleepiness is high. However, deciding that if 1.54 points decrease in ESS is also clinically significant is a bit complex. In this case, we also should consider the qualitative conclusions of studies. Most studies have mentioned deteriorated measures of the day time sleepiness in narcolepsy following the lockdowns [10, 13-14]. while reports of improvement in subjective sleepiness struggled along [15,16]. Zhao et al. attributed this improvement in daytime symptoms of narcolepsy to increased total sleep time (TST) in lockdown period. Laclause et al. reported various transformations in the time metrics of daytime and night time sleep of NT patients that its interpretation was not comprehensively provided [17]. Therefore, it seems that COVID-19 is affecting sleep quality and day time wakefulness in narcolepsy patients but the direction of the effects is widely distinct in different individuals. Our study findings also justify the finding of decreased day time sleepiness as daytime naps have been being scheduled in treatment process of the narcolepsy patients [18]. However, in patients who their clinical status does not respond to stimulant medications, naps are not recommended [19]. This might be a huge source of heterogenicity in combining data of included studies as we were not able to

pool data of variations in adherence to medications during the COVID-19 pandemic. The most prevalently increased symptom among the narcolepsy patients was naps taken during the day (58.81%, 95%CI of 50.85 to 66.34) followed by the increased appetite (45.15%, 95%CI of 28.91 to 62.49). Increased BMI in narcolepsy patients has been previously studied and cited to be more prevalent than general population [20]. and has been known as a linked disease to narcolepsy [21].

COVID-19 is directly been associated with narcolepsy, based on the SARS-COV2 infected case reports that have experienced excessive daytime sleepiness [22]. The biomolecular mechanisms of such interaction was explained for Influenza virus [23]. But, beyond the pathophysiological investigations, participants with previously diagnosed narcolepsy are known as a population with special care needs and their disease status during the COVID-19 pandemic has been evaluated by some studies that we seek to review.

This study has some limitations in this study. While we used a comprehensive systematic review strategy, there might be studies that were missed by our literature review. In addition, response rate to surveys in some studies were low (26.5% in [24]; 40.71% in [13]. Furthermore, there are various confounding factors that are not controlled in our study, as well as the age, gender, ethnicity [25]., or other known and unknown ones.

#### **Conflict of Interest**

The authors have no conflict of interest to declare.

### **Funding Statement**

This research did not receive any specific grant from funding agencies in the public.

### **Ethical approval**

There is no ethical issue.

# Acknowledgments

The authors would like to thank the Clinical Research Development Unit of Peymanieh Educational and Research and Therapeutic Center of Jahrom University of Medical Sciences for providing facilities to this work

# Orcid:

Mansour Deylami\*:

https://www.orcid.org/0000-0002-5933-3219 Majid Vatankhah: https://www.orcid.org/0000-0002-2053-1138 Tayyebeh Zarei: https://www.orcid.org/0000-0001-8605-7742 Ehsan Rahmanian: https://www.orcid.org/0000-0002-1321-8688 Farshid Javdani: https://www.orcid.org/0000-0002-7850-3519 Shahram Shafa: https://www.orcid.org/0000-0001-9888-4630 Hasan Zabetian: https://www.orcid.org/0000-0002-2507-4431 Minou Najar Nobari: https://www.orcid.org/0009-0000-3010-3543 Kaveh Hedayati Emami: https://orcid.org/0000-0001-5920-396X Fateme Maleki: https://www.orcid.org/0000-0002-6823-5151 Amin Shafiei: https://www.orcid.org/0000-0003-0005-4319 Vida Hafezi: https://www.orcid.org/0009-0005-4287-881X Farzaneh Roohie: https://www.orcid.org/0000-0002-0892-1555 Mohammad Sadegh Sanie Jahromi: https://www.orcid.org/0000-0001-8437-1092

# References

[1] V. Chavda, B. Chaurasia, G.E. Umana, S.O. Tomasi, B. Lu, N. Montemurro, Narcolepsy-A Neuropathological Obscure Sleep Disorder: A Narrative Review of Current Literature, *Brain Sci.*, **2022**, *12*, 1473. [Crossref], [Google Scholar], [Publisher] Journal of Medicinal and Pharmaceutical Chemistry Research

SAMI Pag

[2]W.T. Longstreth Jr, T.D. Koepsell, T.G. Ton, A.F. Hendrickson, G. Van Belle, 2007. The epidemiology of narcolepsy, *Sleep*, **2007**, *30*, 13-26. [Crossref], [Google Scholar], [Publisher] [3] R. Broughton, Q. Ghanem, Y. Hishikawa, Y. Sugita, S. Nevsimalova, B. Roth, Life effects of narcolepsy in 180 patients from North

America, Asia and Europe compared to matched controls, *Canadian Journal of Neurological Sciences*, **1981**, *8*, 299-304. [Crossref], [Google Scholar], [Publisher]

[4] P.M. Becker, J.R. Schwartz, N.T. Feldman, R.J. Hughes, Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy, *Psychopharmacology*, **2004**, *171*, 133-139. [Crossref], [Google Scholar], [Publisher]

[5] S. Abiri, A. Ghanaatpisheh, M. Sohrabpour, M.S.S. Jahromi, S.R. Habibzadeh, B. Shahi, M. Foroughian, F. Maleki, A. Hakemi, E.R. Dost, A. Kazeminezhad, Worldwide One-Year Dynamics Of COVID-19 Manifestations: A Systematic Review And Meta-Analysis, *Updates in Emergency Medicine*, **2022**, *2*, 23-33. [Google Scholar], [Publisher]

[6] a) H. Onyeaka, C.K. Anumudu, Z.T. Al-Sharify, E. Egele-Godswill, P. Mbaegbu, COVID-19 pandemic: A review of the global lockdown and its far-reaching effects, *Science progress*, **2021**, *104*, 368504211019854. [Crossref], [Google Scholar], [Publisher] b) M. Khosravani, A. Karimi, S. Khaki, H. Parnikh, A. Moslemi, Z. Mostafapour, A. Amiri, Clinical Changes in Patterns of Moral Courage and Moral Distress Among Operating Room Nurses During COVID-19, *Journal of Medicinal and Chemical Sciences*, **2023**, *7*, 91-103. [Crossref], [Publisher]

[7] G. Motazedian, P. Aryanpoor, E. Rahmanian, S. Abiri, N. Kalani, N. Hatami, F. Bagherian, M. Etezadpour, R. Farzaneh, F. Maleki, M. Foroughian, Incidence of pediatric perforated appendicitis during the COVID-19 pandemic; a systematic review and meta-analysis, *Archives of Academic Emergency Medicine*, **2022**, *10* [Crossref], [Google Scholar], [Publisher]

[8] A.C. Rodrigues Aguilar, C. Frange, L. Huebra, A.C. Dias Gomes, S. Tufik, Santos F.M. Coelho, The effects of the COVID-19 pandemic on



patients with narcolepsy, *Journal of Clinical Sleep Medicine*, **2021**, *17*, 621-627. [Crossref], [Google Scholar], [Publisher]

[9]W.C. Chin, Y.S. Huang, I. Tang, P.Y. Lee, C.H. Wang, K.Y. Chao, Impact of Taiwan's 2021 COVID-19 lockdown on the symptom severity and quality of life of patients with narcolepsy, *Sleep and Biological Rhythms*, **2023**, 1-11. [Crossref], [Google Scholar], [Publisher]

[10] a) E. Postiglione, F. Pizza, F. Ingravallo, L. Vignatelli, M. Filardi, A. Mangiaruga, E. Antelmi, M. Moresco, C. Oriolo, U. Pagotto, G. Plazzi, Impact of COVID-19 pandemic lockdown on narcolepsy type 1 management, *Brain and behavior*, **2021**, *11*, 1955. [Crossref], [Google Scholar], [Publisher] b) B. hosouna, H. Malek, S.M. Abdelsalam, Z. Ahwidy, Computational study of the effectiveness of natural herbal derivatives on COVID-19 virus, *Advanced Journal of Chemistry-Section B: Natural Products and Medical Chemistry*, **2021**, *3*, 323-332. [Crossref], [Google Scholar], [Publisher]

[11] V. Mogharab, M. Ostovar, J. Ruszkowski, S.Z.M. Hussain, R. Shrestha, U. Yaqoob, P. Aryanpoor, A.M. Nikkhoo, P. Heidari, A.R. Jahromi, E. Rayatdoost, Global burden of the COVID-19 associated patient-related delay in emergency healthcare: a panel of systematic review and meta-analyses, *Globalization and health*, **2022**, *18*, 58. [Google Scholar], [Publisher]

[12] a) S. Nouri, E.C. Khoong, C.R. Lyles, L. Karliner, Addressing equity in telemedicine for chronic disease management during the Covid-19 pandemic, *NEJM Catalyst Innovations in Care Delivery*, **2020**, *1*. [Google Scholar], [Publisher] b) N. Shokrian, H.O. Osquee, A Systematic Review Regarding the Diagnosis, Symptoms, and Methods of Home Quarantine in Children during Covid-19 Pandemic, *Progress in Chemical and Biochemical Research*, **2023**, *6*, 88-97. [Crossref], [Publisher]

[13] L. Barateau, S. Chenini, A.L. Rassu, C. Denis, Q. Lorber, C. Dhalluin, R. Lopez, I. Jaussent, S. Beziat, Y. Dauvilliers, Changes in sleep pattern during the COVID-19 lockdown in patients with narcolepsy, idiopathic hypersomnia, and restless legs syndrome,

*Neurology*, **2022**, *99*, 1475-e1485 [Crossref], [Google Scholar], [Publisher]

[14] M. Filardi, A. D'Anselmo, A. Mazzoni, M. Moresco, F. Pizza, G. Plazzi, The importance of social zeitgeber in paediatric type 1 narcolepsy: What we can learn from the COVID-19 restrictions adopted in Italy?, *Journal of Sleep Research*, **2022**, *31*, 13423. [Crossref], [Google Scholar], [Publisher]

[15] M. Zhao, B. Zhang, J. Tang, X. Zhang, The impact of sleep pattern in school/work performance during the COVID-19 home quarantine in patients with narcolepsy, *Frontiers in Neurology*, **2022**, *13*, 849804. [Crossref], [Google Scholar], [Publisher]

[16] a) A. D'Anselmo, S. Agnoli, M. Filardi, F. Pizza, S. Mastria, G.E. Corazza, G. Plazzi, Being creative during lockdown: The relationship between creative potential and COVID-19related psychological distress in narcolepsy type 1, Journal of Sleep Research, 2022, 31, 13461. [Crossref], [Google Scholar], [Publisher] S. Javame, b) М. Ghods, Examination of Four Antiviral Drugs by Studying Their Polynomials and Topological Indices, Chemical Methodologies, 2023, 7, 67-80. [Crossref], [Google Scholar], [Publisher]

[17] A. Pech de Laclause, E. Konofal, P. Bokov, C. Delclaux, M. Lecendreux, Adjustment to lockdown in children and adolescents with narcolepsy in France, *Journal of Clinical Sleep Medicine*, **2022**, *18*, 2247-2252. [Crossref], [Google Scholar], [Publisher]

[18] J. Mullington, R. Broughton, Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy, *Sleep*, **1993**, *16*, 444-456. [Crossref], [Google Scholar], [Publisher]

[19] A.E. Rogers, M.S. Aldrich, X. Lin, A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy, *Sleep*, **2001**, *24*, 385-391. [Crossref], [Google Scholar], [Publisher]

[20] N. Dahmen, J. Bierbrauer, M. Kasten, Increased prevalence of obesity in narcoleptic patients and relatives, *European archives of psychiatry and clinical neuroscience*, **2001**, *251*, 85-89. [Crossref], [Google Scholar], [Publisher]





[21] L.E. Krahn, W.R. Moore, S.I. Altchuler, Narcolepsy and obesity: remission of severe cataplexy with sibutramine, *Sleep medicine*, **2001**, *2*, 63-65. [Crossref], [Google Scholar], [Publisher]

[22] M. Shabani, B. Rahimi, M.M.M. Nejad, R. Erfanian, A. Najafi, Daytime Hypersomnolence in COVID-19: A Case Report and Literature Review, *Acta Medica Iranica*, **2021** [Crossref], [Google Scholar], [Publisher]

[23] C. Tesoriero, A. Codita, M.D. Zhang, A. Cherninsky, H. Karlsson, G. Grassi-Zucconi, G. Bertini, T. Harkany, K. Ljungberg, P. Liljeström, T.G. Hökfelt, H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep–wake regulatory neurons in mice, *Proceedings of the National Academy of Sciences*, **2016**, *113*, 368-377. [Crossref], [Google Scholar], [Publisher]

[24] M. Nigam, A. Hippolyte, P. Dodet, A. Gales, J.B. Maranci, S. Al-Youssef, S. Leu-Semenescu, I. Arnulf, Sleeping through a pandemic: impact of COVID-19–related restrictions on narcolepsy and idiopathic hypersomnia, *Journal of Clinical Sleep* 

Medicine, **2022**, 18, 255-263. [Crossref], [Google Scholar], [Publisher]

[25] N. Kalani, N. Hatami, S. Ali, M. Haghbeen, U. Yaqoob, E.R. Dost, Covid-19 health care for afghan refugees as a minor ethnicity in iran; clinical differences and racial equality in health, *Clinical Differences and Racial Equality in Health*, **2021**. [Crossref], [Google Scholar], [Publisher]

How to cite this article: Mansour Deylami\*, Majid Vatankhah, Tayyebeh Zarei, Ehsan Rahmanian, Farshid Javdani, Shahram Shafa, Hasan Zabetian, Minou Najar Nobari, Kaveh Hedavati Emami, Fateme Maleki, Amin Farzaneh Roohie, Shafiei, Vida Hafezi, Mohammad Sadegh Sanie Iahromi. Systematic review and meta-analysis of narcolepsy management during the covid-19 and pandemic. Journal of Medicinal Pharmaceutical Chemistry Research, 2024, 292-301. 6(3), Link: http://jmpcr.samipubco.com/article\_18436 5.html

Copyright © 2024 by SPC (<u>Sami Publishing Company</u>) + is an open access article distributed under the Creative Commons Attribution License(CC BY) license (<u>https://creativecommons.org/licenses/by/4.0/</u>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.